Morgan Stanley Reiterates Overweight Rating on Solazyme Following Roquette JV Announcement

In a report published Monday, Morgan Stanley analyst Charles A. Dan reiterated an Overweight rating on Solazyme (NASDAQ: SZYM ). In the report, Morgan Stanley noted, “Solazyme's announcement of the dissolution of their JV with Roquette is clearly a negative headline, but represents only a small impact on the near